Ovarian Cancer Clinical Trial
Official title:
PURSUE - Psychosexual Consequences of Risk-reducing Salpingooophorectomy in BRCA1/2 Mutation Carriers
Short Rationale: Risk-reducing salpingo-oophorectomy (RRSO) is a mainstay in preventing
ovarian cancer in BRCA1/2 mutation carriers, as ovarian cancer screening is ineffective in
detecting ovarian cancer in an early and curable stage. Women who underwent RRSO experienced
bothersome menopausal symptoms and worsening of sexual functioning related to acute surgical
menopause. Hormone replacement therapy (HRT) will mitigate some of the RRSO induced
menopausal complaints, however it does not reduce the complaints to a premenopausal level and
the sexual symptoms are not alleviated. Mindfulness interventions were found to improve
sexual functioning and alleviate menopausal symptoms in various populations. It has not been
investigated whether mindfulness-based stress reduction (MBSR) is effective in mitigating the
RRSO-induced menopausal complaints in BRCA1/2 mutation carriers and if this effect is
sustained over a longer period of time.
Objective: To examine the effect of MBSR training on the menopause-specific quality of life
in BRCA1/2 mutation carriers who experience RRSO-induced menopausal complaints.
Study population: Female BRCA1/2 mutation carriers who were younger than 52 years at the time
of RRSO reporting two or more moderate to severe menopause related complaints after
undergoing RRSO.
Study design: Prospective randomized controlled trial with a follow-up time of twelve months
conducted at the University Medical Center Groningen (UMCG)
Intervention: Eight-week MBSR training consisting of a weekly class of two and half hours and
a full retreat day. Furthermore participants are asked to practice mindfulness exercises at
home for 45 minutes, six days a week.
Main study parameters/endpoints: Menopause specific quality of life score measured by the
Menopause-specific quality of life questionnaire (MENQOL). Nature and extent of the burden
and risks associated with participation, benefit and group relatedness: There are no risks
associated with taking part in a MBSR training or filling out the questionnaires that will be
used in this study. The content of the questionnaires concerns intimate matters and could be
considered burdensome. A possible benefit for the participants of the MBSR training is that
participants will be more able to cope with their complaints after RRSO. The group
relatedness is reflected in the fact that RRSO is specifically performed in women with a
hereditary risk of ovarian cancer such as BRCA1/2 mutation carriers.
OBJECTIVES This study will evaluate the effectiveness of a mindfulness-based intervention in
alleviating RRSO-induced menopausal complaints in BRCA1/2 mutation carriers. The intervention
to be tested is MBSR training. The investigators hypothesize that women in the MBSR group
will report statistically significantly greater improvement of menopause-specific quality of
life from baseline to twelve weeks when compared to the control group and that this
improvement will be maintained at six months and twelve months. The investigators also
hypothesize that women in the MBSR group will report a statistically significantly greater
improvement in sexual functioning and a decrease in sexual distress from baseline to twelve
weeks when compared to the control group and that this improvement will be maintained at six
and twelve months.
The primary objective is to examine the effect of MBSR training on the menopause-specific
quality of life in BRCA1/2 mutation carriers who experience RRSO-induced menopausal
complaints.
The secondary objective is to examine the effect of MBSR training on sexual functioning and
distress in BRCA1/2 mutation carriers who experience RRSO-induced menopausal complaints.
STUDY DESIGN The study is a prospective, randomized controlled trial, with an intervention
group that receives an eight-week MBSR training as well as care as usual and a control group
that only receives care as usual. All participants will be asked to fill out questionnaires
regarding menopausal and sexual complaints at baseline before randomization (T0) and at
twelve weeks (T1), six (T2) and twelve months (T3) after randomization. The study will be
conducted at the family cancer clinic of the UMCG.
STATISTICAL ANALYSIS The two treatment arms will be summarized at baseline with frequencies
for categorical variables and means, ranges and SDs for continuous variables. Scores for the
MenQOL, FSFI and FSDS will be calculated according to published scoring algorithms.
A linear mixed effects analysis will be performed on the relationship between the MenQOL
score and the intervention. The scores on the MenQOL at 12 weeks, 6 months and 12 months will
be modelled as a function of treatment arm, time moment, their interaction. An unstructured
correlation matrix will be assumed, unless the data indicate the presence of another
correlation structure. If the groups are unbalanced, covariates will added to the model. All
analysis will be conducted on an intention-to-treat basis. All analyses will be performed
with SPSS.
Similar analyses will be conducted for the FSFI and FSDS, which will be used as a secondary
outcome measure.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |